Last reviewed · How we verify
Mirikizumab (MIR)
Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in immune-mediated diseases.
Mirikizumab is a monoclonal antibody that selectively inhibits the IL-23 p19 subunit, reducing IL-23 signaling in immune cells to suppress inflammatory responses. Used for Ulcerative colitis, Crohn's disease.
At a glance
| Generic name | Mirikizumab (MIR) |
|---|---|
| Also known as | Omvoh |
| Sponsor | Alimentiv Inc. |
| Drug class | IL-23 inhibitor monoclonal antibody |
| Target | IL-23 p19 subunit |
| Modality | Small molecule |
| Therapeutic area | Immunology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
IL-23 is a key cytokine involved in the differentiation and expansion of pro-inflammatory T cells, particularly Th17 cells. By blocking the p19 subunit of IL-23, mirikizumab prevents IL-23-mediated immune activation and reduces pathogenic inflammation. This mechanism is particularly relevant in conditions driven by IL-23-dependent immune responses, such as inflammatory bowel disease.
Approved indications
- Ulcerative colitis
- Crohn's disease
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mirikizumab (MIR) CI brief — competitive landscape report
- Mirikizumab (MIR) updates RSS · CI watch RSS
- Alimentiv Inc. portfolio CI